萊茵生物(002166.SZ):與帝斯曼-芬美意續簽日常經營重大合同
格隆匯6月18日丨萊茵生物(002166.SZ)公佈,2023年6月16日,公司與dsm-firmenich(帝斯曼-芬美意)簽署了未來5年合作的新協議,本協議累計目標收入(CTR)金額為8.4億美元(含税,下同),最低累計目標收入(MCTR)金額為6.8億美元,協議期限為5年。
芬美意是全球四大香精香料企業之一,也是全球最著名的食品香精香料公司,在全球擁有較高的知名度,技術能力和銷售額均在世界同行業中名列前茅。2023年5月9日,芬美意與帝斯曼正式合併為dsm-firmenich(帝斯曼-芬美意),根據帝斯曼官網顯示,帝斯曼是一家專注健康、營養和生物科學的全球科學領導者,在全球範圍內擁有35個科研實驗室,約1,500名科學家,其產品被廣泛應用於食品、健康、營養、個人護理、動物營養、製藥等多個應用市場,在多個應用領域位於世界前列。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.